Immunome

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It focuses on oncology and infectious disease areas. It utilizes the proprietary human memory B cell platform to enable the discovery of novel antibodies in both these therapeutic areas because of the interrogation of memory B cells from patients who have learned to fight off these diseases. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

IMNM is set to merge with Morphimmune, pending a shareholder vote on September 29. The current CEO of Morphimmune, Clay Siegall, would become the new CEO of IMNM. Siegall co-founded and led Seagen for over 20 years. Immunome intends to raise $125M via a PIPE, which is oversubscribed, providing the company with sufficient funds to develop the potential merged pipeline.

Immunome: The Morphimmune Merger And The Pipeline

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We believe combining Immunome and Morphimmune's technologies represents a major step in our long-term strategy of creating a preeminent oncology therapeutics company,”.

Immunome Reports Second Quarter 2023 Financial Results

MILWAUKEE , June 30, 2023 /PRNewswire/ -- Ademi LLP is investigating Immunome (Nasdaq: IMNM) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Morphimmune.  Click here to learn how to join the action https://www.ademilaw.com/case/Immunome-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Immunome, Inc. has obtained a Fair Price in its Private Placement and its transaction with Morphimmune

Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.

Immunome (IMNM) Surges on Merger Agreement With Morphimmune

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the all-stock merger of Morphimmune and Immunome, Inc. (NASDAQ: IMNM) is fair to Immunome shareholders. Halper Sadeh encourages Immunome shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Immunome and its board violated the f.

IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders

EXTON, Pa. & SEATTLE--(BUSINESS WIRE)--Immunome (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B-cell platform to discover and develop antibody therapeutics to improve patient care, and Morphimmune, a private biotechnology company focused on developing targeted oncology therapeutics, today announced that they have entered into a definitive merger agreement. The Boards of Directors of both companies have approved the all-stock transaction. The combined company,.

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled “IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation,” in the peer-reviewed journal mAbs. The data in the article d.

Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The external validation of our Discovery Engine through our collaboration with AbbVie underlines the need for disruptive technologies that can shape the progress of can.

Immunome Reports First Quarter 2023 Financial Results

If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunome, Inc. (IMNM) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Immunome, Inc. (IMNM) is on the Move, Here's Why the Trend Could be Sustainable

Recent Price Trend in Immunome, Inc. (IMNM) is Your Friend, Here's Why

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update.

Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13th Annual World ADC London conference, taking place from March 13-16, 2023.

Immunome to Present at 13th Annual World ADC London Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that discovers novel target-antibody pairs through its unbiased interrogation of the human immune response, today announced the formation of an advisory board, comprised of Dr. John Lambert and Dr. Anthony Tolcher, to prioritize selection of novel targets for antibody drug conjugates (ADCs) and T cell redirection (TCR) modalities.

Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Topline data from Immunome's phase 1b trial of its COVID antibody drug, IMM-BCP-01, have led the company to look for a partner for further development. Even if IMNM can't find a partner for IMM-BCP-01, a new collaboration agreement with ABBV is arguably a more exciting development.

Immunome: Clinical Data With A COVID Therapeutic And The AbbVie Collaboration

AbbVie

AbbVie stock briefly broke out Friday after the company signed a $30 million deal with small biotech Immunome in antibody development. The post AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal appeared first on Investor's Business Daily.

AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal

Immunome and AbbVie announced a worldwide collaboration and option agreement to discover up to 10 new antibody-target pairs for treating three specific types of tumors using Immunome's technology.

AbbVie and Immunome Partner to Find New Cancer Treatments

- Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine - Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties NORTH CHICAGO, Ill. and EXTON, Pa.

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

EXTON, Pa.--( BUSINESS WIRE )--Immunome, Inc. (Nasdaq: IMNM), a clinical stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Immunome Reports Third Quarter 2022 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it is presenting a poster at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting in Boston, Massachusetts highlighting the Company's preclinical data of IMM20059, a novel anti-epsin 1(EPN1) antibody.

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced the publication of a peer-reviewed article in Clinical & Translational Immunology characterizing B cell repertoires in tissue samples from patients with breast cancer. In collaboration with groups at the University of Vermont Larner College of Medicine and the University of Pennsyl

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “The second quarter marked our transition into a clinical stage company, as we continue to dose patients in our Phase 1b study of our COVID-19 antibody cocktail, IMM-BCP-01,” stated Purnanand S

Immunome Reports Second Quarter 2022 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that their cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing. IMM-BCP-01 is currently in Phase 1b clinical testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5 an

Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced the first patient has been enrolled in a clinical trial of IMM-BCP-01, a three-antibody cocktail for the treatment of SARS-CoV-2 (COVID-19). Topline data is expected in the second half of this year, which is an update from our prior guidance. The Phase 1b study of IMM-BCP-01 is a singl

Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, PhD, President and CEO of Immunome, will present at the Jefferies Healthcare Conference on Thursday, June 9, at 2:30 p.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at w

Immunome to Present at the Jefferies Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced updates to the ongoing development of its lead oncology program, IMM-ONC-01, a novel immuno-oncology agent that inhibits IL-38, an immunosuppressive cytokine. Preclinical research conducted by Immunome, and literature evidence1,2, suggests IL-38 dampens natural anti-tumor immune respon

News for Immunome Stock (IMNM)